Palbocib (Palbociclib) 125 mg
Palbocib-125 (Palbociclib 125 mg) is a CDK4/6 inhibitor, a class of drugs that has revolutionized the treatment of metastatic breast cancer.
Manufacturer: Aprazer (India). A generic equivalent to Ibrance.
Mechanism ("The Cellular Brake"):
Cancer cells often have overactive CDK4/6 proteins that drive them to divide uncontrollably. Palbociclib blocks these proteins, effectively stopping the cell division cycle. It works synergistically with hormonal therapy to delay disease progression significantly.
✅ Key Benefit: Offers a chemotherapy-free option that maintains quality of life for longer.
Indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer in women:
- In combination with an aromatase inhibitor (e.g., Letrozole) as initial endocrine-based therapy.
- In combination with Fulvestrant in women with disease progression following endocrine therapy.
Standard Dosage: 125 mg once daily.
⚠️ THE "21/7" CYCLE RULE:
- 📅 Days 1–21: Take one capsule daily.
- 🛑 Days 22–28: Take NO medication (7-day break). This allows your white blood cell count to recover.
- Repeat the cycle.
🍔 Food Requirement: Take this capsule WITH FOOD. Food significantly increases the absorption of the drug.
- Pregnancy and breastfeeding.
- Severe neutropenia (low white blood cell count).
- Hypersensitivity to Palbociclib.
- Avoid grapefruit and grapefruit juice.
Regular blood tests (CBC) are mandatory:
- 📉 Neutropenia: Low count of neutrophils (white blood cells) is extremely common. It is usually reversible during the 7-day break.
- Fatigue: Feeling tired or weak.
- Infections: Due to lowered immunity.
- Hair thinning (Alopecia).
Similar products
What Customers Say
No reviews yet
Your review can be the first!